$Fortress Biotech (FBIO.US)$Fortress Biotech's Urica Therapeutics Entered Into An APA Royalty Agreement, Urica Sold The Rights To Its URAT1 Inhibitor Product Candidate In Development For The Treatment Of Gout, Dotinurad, And Related Intellectual Property, Licenses And Agreements To Crystalys Therapeutics In Return For Common Stock Equal To 35% Of Crystalys' Outstanding Equity - SEC Filing
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more